Akt–the Mammalian Target of Rapamycin (mTOR) Pathway Inhibition Increases Cervical Cancer Cell Chemosensitivity to Active Form of Irinotecan (SN-38). International Journal of Integrated Health Sciences, v. 1, n. 1, p. 13–21, 17 Sep.2013.